Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Xeris Biopharma Holdings (XERS) Intangibles (2021 - 2025)

Historic Intangibles for Xeris Biopharma Holdings (XERS) over the last 5 years, with Q3 2025 value amounting to $90.8 million.

  • Xeris Biopharma Holdings' Intangibles fell 1066.89% to $90.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $90.8 million, marking a year-over-year decrease of 1066.89%. This contributed to the annual value of $98.9 million for FY2024, which is 987.85% down from last year.
  • Per Xeris Biopharma Holdings' latest filing, its Intangibles stood at $90.8 million for Q3 2025, which was down 1066.89% from $93.5 million recorded in Q2 2025.
  • Over the past 5 years, Xeris Biopharma Holdings' Intangibles peaked at $131.4 million during Q4 2021, and registered a low of $90.8 million during Q3 2025.
  • Moreover, its 5-year median value for Intangibles was $111.1 million (2023), whereas its average is $111.1 million.
  • Per our database at Business Quant, Xeris Biopharma Holdings' Intangibles tumbled by 824.88% in 2022 and then plummeted by 1066.89% in 2025.
  • Xeris Biopharma Holdings' Intangibles (Quarter) stood at $131.4 million in 2021, then dropped by 8.25% to $120.6 million in 2022, then dropped by 8.99% to $109.8 million in 2023, then fell by 9.88% to $98.9 million in 2024, then fell by 8.22% to $90.8 million in 2025.
  • Its Intangibles stands at $90.8 million for Q3 2025, versus $93.5 million for Q2 2025 and $96.2 million for Q1 2025.